Needles, Not Stigma: Fiji’s Harm Reduction Law and the Politics of an HIV Emergency

Genevieve Phillips | South Pacific Fellow 

Image sourced from Bakytzhan Baurzhanov via Pexels

Fiji’s HIV/AIDS (Amendment) Bill 2026 is one of the clearest recent examples of Pacific states moving decisively to remove legal barriers that were actively costing lives. The three-clause amendment, passed by Parliament in early October, gives the Health Minister the authority to authorise formal harm-reduction programmes such as the free distribution of sterile needles and syringes. It is a pragmatic public-health response to a national emergency. It can also be seen as a quiet assertion of agency: Fiji chose evidence over stigma at a moment when injecting drug use has become a major driver of the fastest-growing HIV epidemic in the world.

From Emergency to Legislation

In mid-September 2026, Health Minister Dr Ratu Atonio Lalabalavu declared a national HIV emergency. Current estimates put prevalence at approximately one in every 60 adults. In 2025 alone, Fiji recorded 2,016 new diagnoses, a 27 per cent increase on the previous year and among the sharpest rises globally. Of cases with a known mode of transmission, more than 40 per cent were linked to injecting drug use, including the high-risk practice of “bluetoothing”, a term that refers to the dangerous sharing of drug-infused blood between users. The epidemic has also reached pregnant women and infants: 59 babies were born with HIV in 2025, 18 of whom died before their first birthday.

By the time the emergency was declared, the Ministry already had stockpiles of sterile needles and syringes sitting in a Suva warehouse. The immediate obstacle was legal. Under the existing HIV/AIDS Act 2011, distributing injecting equipment risked exposing health workers and outreach teams to criminal liability. The Amendment Bill removed that barrier, inserting a new Section 26 empowering the Minister to direct the Ministry, the HIV/AIDS Board, or authorised persons to implement harm-reduction programmes. These may include free distribution of sterile needles and syringes, condoms, and lubricant, pre- and post-exposure prophylaxis (PrEP and PEP), counselling, awareness materials, safe disposal facilities and referrals to treatment and rehabilitation services. Critically, the law provides legal protection for those acting within an authorised programme, while explicitly stating that it does not legalise illicit drugs or reduce penalties for drug offences.

Evidence Over Ideology

Needle and syringe programmes are among the most thoroughly evaluated public health interventions available. Decades of evidence from Australia, New Zealand and elsewhere show that they reduce HIV and hepatitis C transmission among people who inject drugs without increasing overall drug use. Fiji now joins Australia, New Zealand and Papua New Guinea as the only Pacific nations with a formal programme of this kind.

The decision to legislate rather than rely on informal or pilot arrangements is significant. It creates a durable legal foundation, protects frontline workers and signals that the government is prepared to prioritise transmission prevention over moral discomfort. Peer outreach workers are expected to play a central role in distributing and collecting used equipment, a design choice that recognises the importance of trust and community reach in populations often excluded from mainstream health services.

The Implementation Test

Passing the law was the necessary first step; the harder work lies ahead. Success will depend on the speed and geographic coverage of the rollout; the quality of linkage between needle distribution, HIV testing, treatment and rehabilitation services; genuine community ownership through peer workers; and the government's ability to protect the programme from political or moral backlash once it becomes visible in communities.

Stigma remains a powerful barrier. Health Minister Lalabalavu has repeatedly urged Fijians not to shame or exclude people living with HIV, noting that stigma drives people away from the very services that can help them. Whether that message is sustained as the programme expands will shape uptake and impact.

Pacific Agency and Australia’s Role

Fiji’s response demonstrates a form of Pacific agency that is often overlooked: the capacity to diagnose a crisis, identify an evidence-based solution, and remove the legal obstacle standing in its way, even when the solution is politically sensitive. The surge in injecting drug use is closely linked to trafficking routes that supply Australia’s high demand market. Australia’s high domestic demand is a major driver of these routes, which has left several Pacific nations grappling with rising drug use and its public-health consequences. Papua New Guinea and Tonga, in particular, are reporting increasing rates of injecting drug use alongside concerning rises in new HIV infections.Other Pacific states facing rising injection drug use and HIV transmission will be watching closely.

For Australia, the development poses a practical and principled decision. Canberra has long experience with needle and syringe programmes and is a major health and development partner in the region. The choice is whether to support Fiji’s programme as a genuine partner in regional health security through technical assistance, resource provision, peer learning or quiet diplomatic backing, or to treat it as another arena for influence. The former would reinforce the claim to be partner of choice. The latter would risk repeating a familiar pattern in which Pacific initiative is welcomed in principle but shaped by external priorities in practice.

The Amendment Bill removes a legal barrier that was actively enabling transmission and establishes a platform for a more effective, rights-based response. However, legislative reform and needle and syringe programmes alone cannot end Fiji’s HIV emergency or solve the underlying drug crisis. Addressing the growth of drug trafficking through the Pacific requires leadership and partnerships that extend beyond public health, including action from countries like Australia whose demand helps sustain these markets. Other Pacific states facing similar challenges will be watching how Australia responds.

Genevieve Phillips is a Bachelor of Law/Arts (History) student and 2025 New Colombo Plan Scholar currently on exchange in Fiji. She focuses on international environmental law, ocean governance, and Australia–Pacific relations. She is passionate about elevating Pacific perspectives, especially on climate mobility and maritime governance, by writing about issues affecting the region that may not be mainstream knowledge for young people, drawing on her lived experience to inform her article topics.

Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the views and opinions of Young Australians in International Affairs. AI tools were used by this author for structural editing and idea refinement, but all analysis, argument and content are original, and no plagiarism has been used in the preparation of this article.